
Keywords: Ezetimibe; PCSK9 inhibitors; Lipid-lowering therapy; Atherosclerosis; Plaque regression; ACS; acute coronary syndrome; ASCVD; atherosclerotic cardiovascular disease; CuVIC; Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction Afte